Cocaine abusers have an overexpression of α-synuclein in dopamine neurons

Journal of Neuroscience

Volumn 23, Issue 7, 2003, Pages 2564-2571

  Mash, Deborah C ^a   Ouyang, Qinjie ^a   Pablo, John ^a   Basile, Margaret ^a   Izenwasser, Sari ^a   Lieberman, Abraham ^a   Perrin, Richard J ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Brain; Cocaine; DA; Delirium; Postmortem; Synucleins

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; COCAINE; DOPAMINE;

ADULT; AGITATION; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DELIRIUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; FEMALE; GENE OVEREXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HYPERTHERMIA; LEWY BODY; MALE; OXIDATIVE STRESS; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; WESTERN BLOTTING;

EID: 0037390023     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-07-02564.2003     Document Type: Article

References (68)

1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal DA system. Neuron 25:239-252.
2. Bartzokis G, Beckson M, Ling W (1996) Clinical and MRI evaluation of psychostimulant neurotoxicity. NIDA Res Monogr 163:300-317.
3. Bartzokis G, Beckson M, Wirshing DA, Lu PH, Foster JA, Mintz J (1999) Choreoathetoid movements in cocaine dependence. Biol Psychiatry 45:1630-1635.
4. Bauer LO (1996) Psychomotor and electroencephalographic sequelae of cocaine dependence. NIDA Res Monogr 163:66-93.
5. Bennett BA, Hyde CE, Pecora JR, Clodfelter JE (1993) Differing neurotoxic potencies of methamphetamine, mazindol, and cocaine in mesencephalic cultures. J Neurochem 60:1444-1452.
6. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
7. Brown JM, Hanson GR, Fleckenstein AE (2001) Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 296:762-767.
8. Canales JJ, Graybiel AM (2000) A measure of striatal function predicts motor stereotypy. Nat Neurosci 3:377-383.
9. Clayton DE, George JM (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21:249-254.
10. Clayton DE, George JM (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58:120-129.
11. Conway KA, Rochet JC, Bieganski RM, Lansbury Jr PT (2001) Kinetic stabilization of the α-synuclein protofibril by a DA-α-synuclein adduct. Science 294:1346-1349.
12. Cubells JF, Rayport S, Rajendran G, Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and DA-dependent intracellular oxidative stress. J Neurosci 14:2260-2271.
13. Dauer W, Kholodilov N, Vila M, Trillat A-C, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, Hen R (2002) Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99:14524-14529.
14. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H (2002) Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413-426.
15. Ellison G, Switzer RC (1993) Dissimilar patterns of degeneration in brain following four different addictive stimulants. NeuroReport 5:17-20.
16. Escobedo LG, Ruttenber AJ, Agocs MM, Anda RF, Wetli CV (1991) Emerging patterns of cocaine use and the epidemic of cocaine overdose deaths in Dade County, Florida. Arch Pathol Lab Med 115:900-905.
17. Feany MB, Bender WWA (2000) Drosophila model of Parkinson's disease. Nature 404:394-398.
18. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272.
19. George JM, Jin H, Woods WS, Clayton DF (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361-372.
20. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
21. Giros B, Caron MG (1993) Molecular characterization of the DA transporter. Trends Pharmacol Sci 14:43-49.
22. Hastings TG, Lewis DA, Zigmond MJ (1996) Role of oxidation in the neurotoxic effects of intrastriatal DA injections. Proc Natl Acad Sci USA 93:1956-1961.
23. Hsu LJ, Mallory M, Xia Y, Veinbergs I, Hashimoto M, Yoshimoto M, Thal LJ, Saitoh T, Masliah E (1998) Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/α-synuclein) during murine brain development. J Neurochem 71:338-344.
24. Hurd YL, Herkenham M (1993) Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13:357-369.
25. Jenco JM, Rawlingston A, Daniels B, Morris AJ (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry 37:4901-4909.
26. Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, Gliemann J, Jakes R (1997) Binding of Abeta to alpha- and beta-synucleins: identification of segments in the alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J 323:539-546.
27. Kholodilov NG, Neystat M, Oo TF, Lo SE, Larsen KE, Sulzer D, Burke RE (1999) Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J Neurochem 73:2586-2599.
28. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ (2000) MPTP induces α-synuclein aggregation in the substantia nigra of baboons. NeuroReport 11:211-213.
29. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18:106-108.
30. Langston JW, Sastry S, Chan P, Forno LS, Bolin LM, Di Monte DA (1998) Novel α-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Exp Neurol 154:684-690.
31. Lavedan C (1998) The synuclein family. Genome Res 8:871-880.
32. Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and functional coupling of α-synuclein to the DA transporters accelerate DA-induced apoptosis. FASEB J 15:916-926.
33. 3H]WIN 35, 428 binding sites in human striatum. Brain Res 628:17-25.
34. Little KY, McLaughlin DP, Zhang L, McFinton PR, Dalack GW, Cook Jr EH, Cassin BJ, Watson SJ (1998) Brain DA transporter messenger RNA and binding sites in cocaine users: a postmortem study. Arch Gen Psychiatry 55:793-799.
35. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol 36:518-524.
36. 123I]beta-CIT SPECT measures of DA transporter availability in human cocaine addicts. Psychopharmacology (Berl) 122:358-362.
37. 123I]beta-CIT SPECT. Am J Psychiatry 155:832-834.
38. Maroteaux L, Scheller RH (1991) The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res 11:335-343.
39. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8:2804-2815.
40. Mash DC, Pablo J, Ouyang Q, Hearn WL, Izenwasser S (2002) DA transport function is elevated in cocaine users. J Neurochem 81:292-300.
41. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) DAergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269.
42. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113-1124.
43. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool to primary hippocampal neurons. J Neurosci 20:3214-3220.
44. Neystat M, Lynch T, Przedborski S, Kholodilov N, Rzhetskaya M, Burke RE (1999) Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov Disord 14:417-422.
45. Paik SR, Lee JH, Kim DH, Chang CS, Kim YS (1998) Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (Abeta) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal Abeta fragment (residues 25-35). FEBS Lett 421:73-76.
46. Pascual-Leone A, Dhuna A, Anderson DC (1991) Cerebral atrophy in habitual cocaine abusers: a planimetric CT study. Neurology 41:34-38.
47. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandeasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
48. Reith ME, Selmeci G (1992) Radiolabeling of DA uptake sites in mouse striatum: comparison of binding-sites for cocaine, mazindol, and GBR 12935. Naunyn Schmiedebergs Arch Pharmacol 345:309-318.
49. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ (2002) Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp Neurol 175:35-48.
50. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on DA transporters are related to self-administration of cocaine. Science 237:1219-1223.
51. Ruttenber AJ, Lawler-Heavner J, Yin M, Wetli CV, Hearn WL, Mash DC (1997) Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity. J Forensic Sci 42:25-31.
52. Self DW, Nestler EJ (1998) Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend 51:49-60.
53. Solano SM, Miller DW, Augood SJ, Young AB, Penney JB (2000) Expression of α-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann Neurol 47:201-210.
54. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) α-Synuclein in Lewy bodies. Nature 388:839-840.
55. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469-6473.
56. Staley JK, Hearn WL, Ruttenber AJ, Wetli CV, Mash DC (1994) High affinity cocaine recognition sites on the DA transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther 271:1678-1685.
57. Staley JK, Wetli CV, Ruttenber AJ, Hearn WL, Mash DC (1995) Altered DAergic synaptic markers in cocaine psychosis and sudden death. NIDA Res Monogr 153:491.
58. Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of DA. J Neurosci Res 55:659-665.
59. Sulzer D (2001) α-Synuclein and cytosolic DA: stabilizing a bad situation. Nat Med 7:1280-1282.
60. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH (2000) Expression of mutant α-synuclein causes increased susceptibility to DA toxicity. Hum Mol Genet 9:2683-2689.
61. Ueda K, Fukushima H, Masliah E, Xia, Y. Iwai A, Yoshimoto M, Otero DAC, Hondo J, Ihara Y, Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 90:11282-11286.
62. Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Wolf AP, Dewey SL, Handlesman L (1992) Long-term frontal brain metabolic changes in cocaine abusers. Synapse 11:184-190.
63. Wester P, Bateman DE, Dodd PR, Edwardson JA, Hardy JA, Kidd AM, Perry RH, Singh GB (1985) Agonal status affects the metabolic activity of nerve endings isolated from postmortem human brain. Neurochem Pathol 3:169-180.
64. Wetli CV, Fishbain DA (1985) Cocaine-induced psychosis and sudden death in recreational cocaine users. J Forensic Sci 30:873-880.
65. Wetli CV, Mash DC, Karch SB (1996) Cocaine-associated agitated delirium and the neuroleptic malignant syndrome. Am J Emerg Med 14:425-428.
66. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, Shannak K, Deck J, Niznik HB, Kish SJ (1996) Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40:428-439.
67. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002) DA-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat Med 8:600-606.
68. Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR (2000) Overexpression of human α-synuclein causes DA neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res 866:33-43.